Odonate Therapeutics, Inc.
Share · US6760792050 (OTC)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Odonate Therapeutics, Inc.
No Price
Company Profile for Odonate Therapeutics, Inc. Share
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Company Data
Name Odonate Therapeutics, Inc.
Company Odonate Therapeutics, Inc.
Website
https://www.odonate.com
Primary Exchange 
UTC
UTC
ISIN US6760792050
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Kevin C. Tang
Market Capitalization 24 Mrd.
Country United States of America
Currency USD
Employees 0,1 T
Address 3 East 28th Street, 10016 New York City
IPO Date 2017-12-07
Stock Splits
| Date | Split |
|---|---|
| 15.01.2025 | 1:8 |
| 09.04.2024 | 1:5 |
| 08.01.2024 | 1:2000 |
| 08.09.2023 | 1:2000 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | ODTC |
More Shares
Investors who hold Odonate Therapeutics, Inc. also have the following shares in their portfolio:
